<DOC>
	<DOCNO>NCT02013050</DOCNO>
	<brief_summary>To evaluate safety efficacy SGX942 patient receive chemoradiation treatment treatment head neck cancer .</brief_summary>
	<brief_title>A Dose Escalating Study SGX942 Oral Mucositis Patients With Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>Biopsyproven nonmetastatic squamous cell carcinoma mouth oropharynx plan receive standard course concomitant CRT . Patients receive surgery eligible surgery perform within 6 week prior study initiation . Planned receive standard cisplatin chemotherapy administer either weekly every third week . Must able read understand inform consent Adequate birth control method duration study Current mucositis . Prior radiation head neck . Chemotherapy treatment within previous 12 month . Tumors lip , sinus , salivary gland nasopharynx . Unknown primary tumor . Stage 4c metastasis . Evidence significant hepatic , hematologic , immunologic disease . Women pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>